Literature DB >> 6861793

[14C]cadralazine: absorption, distribution and excretion in rat and dog.

G Bonardi, E Rossi, M Pellegatti.   

Abstract

Absorption, distribution and excretion of [14C]cadralazine in rat after oral and i.v. administration of 3 mg/kg were studied. Plasma levels after oral administration of 10 and 45 mg/kg were also evaluated. A direct relation between dose and plasma levels was demonstrated. The drug was well absorbed, disappeared very rapidly from plasma, and was distributed in all the organs examined, with the highest concentration in liver, kidney, and gastrointestinal tract. For more than 4 days excretion was essentially through the urine (75.6% after i.v. and 80% after oral administration), whereas faecal and biliary excretions were quite low. The total recovery was respectively 77.6% and 83.2% after i.v. and oral administration of 3 mg/kg, with the greatest amount (65-70% of the administered dose) appearing in the first 4 to 7 hours. Placental transfer and excretion of radioactivity with milk were demonstrated. Drug-protein binding was 25.9%. Elimination of 14CO2 was not observed. Plasma levels in dog, after oral and i.v. administration of 1 mg/kg of labelled compound, showed similar behaviour to that observed in the rat. Binding of the radioactivity to erythrocytes was found; the radioactivity values observed up to 24 hours were constant with time and not dependent on the decreasing plasma levels. The total recovery (urine and faeces) in the dog over 4 days was 71.1% and 82.1% after oral and i.v. dose, respectively. Preliminary metabolic approaches in rats showed that cadralazine was essentially excreted as unchanged drug in the presence of minor metabolites.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6861793     DOI: 10.1007/BF03189578

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  3 in total

1.  Antihypertensive efficacy of a new long acting hydralazine like vasodilator, ISF 2469 in combination with a betablocker and a diuretic.

Authors:  P van Brummelen; F R Bühler; W Kiowski; P Bolli; O Bertel
Journal:  Int J Clin Pharmacol Biopharm       Date:  1979-10

2.  Pharmacological studies on cadralazine: a new antihypertensive vasodilator drug.

Authors:  C Semeraro; L Dorigotti; S Banfi; C Carpi
Journal:  J Cardiovasc Pharmacol       Date:  1981 May-Jun       Impact factor: 3.105

3.  [3-Hydrazinepyridazine derivatives. III. Synthesis and anti-hypertensive activity of new 3-(2-acylhydrazine)-pyridazine-6-alkylamino substitutes].

Authors:  F Parravicini; G Scarpitta; L Dorigotti; G Pifferi
Journal:  Farmaco Sci       Date:  1979-04
  3 in total
  3 in total

Review 1.  Cadralazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension.

Authors:  D McTavish; R A Young; S P Clissold
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

2.  Disposition and pharmacokinetics of cadralazine and individual metabolites in man.

Authors:  H Schütz; J W Faigle; W Küng; W Theobald
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1985 Apr-Jun       Impact factor: 2.441

3.  Pharmacokinetics of cadralazine in hypertensive patients.

Authors:  G Leonetti; J Parini; M Visconti; R Gradnik
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1988 Oct-Dec       Impact factor: 2.441

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.